---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-000271"
form_type: "8-K"
ticker: "STAA"
cik: "0000718937"
company_name: "STAAR SURGICAL CO"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:22:44.797070+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# STAAR reports prelim Q4 sales $64M, FY22 ICL sales $270M; FY23 outlook $340M

## Summary
- Preliminary Q4 net sales ~$64M; FY2022 net sales ~$284M (ICL $270M, other $14M).
- ICL unit growth 20% Q4 Y/Y, 33% FY2022 Y/Y; U.S. ICL units up 109% Q4 Y/Y.
- FY2023 net sales outlook ~$340M, representing ~25% ICL sales growth over FY2022.
- Cash and equivalents ~$225M, up from $120M three years ago.
- Full FY2022 results expected on/about February 22, 2023.

## SEC filing metadata
- accession: 0001564590-23-000271
- form_type: 8-K
- ticker: STAA
- cik: 0000718937
- company_name: STAAR SURGICAL CO
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/718937/000156459023000271/0001564590-23-000271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/718937/000156459023000271/staa-8k_20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-000271
- JSON: https://secwatch.observer/filing/0001564590-23-000271.json
- Plain text: https://secwatch.observer/filing/0001564590-23-000271.txt

## Key facts
- Earnings Releases
  STAAR SURGICAL CO reported the fourth quarter and fiscal year ended December 30, 2022 results: revenue approximately $64 million for the fourth quarter and approximately $284 million for fiscal 2022. Guidance initiated.
  - Period: the fourth quarter and fiscal year ended December 30, 2022
  - Revenue: approximately $64 million for the fourth quarter and approximately $284 million for fiscal 2022
  - Guidance: initiated
  - Result: preliminary results
  source text: STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported preliminary sales for the fourth quarter and fiscal year ended December 30, 2022. Preliminary net sales were approximately $64 million for the fourth quarter and approximately $284 million for fiscal 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/718937/000156459023000271/0001564590-23-000271-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.